For Patients

WHAT CAN WE DO FOR YOU?

If you’ve recently been diagnosed with breast cancer, it’s natural to have questions and concerns.

Our testing can provide you and your doctor with a detailed profile of your unique tumor to help make more informed treatment decisions.

Your tumor is UNIQUE, your TREATMENT should be too……

Every tumor is different…Why should they all be treated the same?

When you first hear that you have breast cancer, many questions may pop into your head:

  • Will I need chemotherapy?
  • What treatment gives me the best chance at beating this?
  • Will my cancer recur?

These are appropriate questions that you may be asking your doctor. With advancements in cancer medicine, there are genomic tests today that can help answer these questions by uncovering more about your tumor’s biology.

These tests help identify your specific tumor type, the likelihood of its recurrence, and how it may respond to various treatments.

MAMMAPRINT TEST: 70-GENE BREAST CANCER RECURRENCE ASSAY

MammaPrint is the only breast cancer recurrence assay backed peer-reviewed, prospective outcome data. Unlike other tests, you are given definitive Low Risk and High Risk results, eliminating the uncertainty of an intermediate risk score which can affect up to 39% of patients tested. A Low Risk result means you have a 10%, or 1 in 10 chance of your cancer returning without any adjuvent systemic therapy. A High Risk result means you have a 29%, or 3 out of 10 chance of it returning. These results are based on a 10-year follow-up of a reference group of patients who had no additional treatment. A Low Risk result doesn’t guarantee that your cancer will not recur, and a High Risk result doesn’t guarantee that your cancer will. These results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions.

asdasd

Experts Comment, Agendia Breast Cancer Assays – Peter Beitsch, MD

Dr. Peter Beitsch, surgical oncologist in Dallas, discusses how genomic testing can help determine whether or not you need chemotherapy.

BluePrint molecular subtyping provides deeper insight into tumor pathways, uncovering your hidden tumor biology. Molecular subtyping informs your doctor about how the tumor is functioning underneath the surface. Traditional subtyping (such as IHC or FISH) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level, to see which genes are really driving the tumor’s behavior. Combined with MammaPrint, BluePrint will uncover if your breast cancer is Luminal-type (A or B), Basal-type, or HER2-type. These findings are important when determining the treatments that are most appropriate for your specific tumor.

MAMMAPRINT & BLUEPRINT TOGETHER

MammaPrint and BluePrint provide you and your doctor deeper insight into tumor pathways, uncovering your hidden tumor biology. By combining risk of recurrence, with molecular subtyping, you get a clearer picture of how your breast cancer is functioning, leading to more informed treatment decision making. MammaPrint is the first FDA cleared breast cancer recurrence assay, and is the only breast cancer recurrence assay backed by peer-reviewed prospective outcome data.

BluePrint molecular subtyping is the most widely available molecular subtyping assay that identify your potential level of responsiveness to chemotherapy more accurately than IHC/FISH, with better correlation to long-term clinical treatment outcomes.

References

  • Buyse M, et al. J Nat Cancer Institute. 2006; 98:17; 1183-92.
  • American Cancer Society. “ Tamoxifen and Raloxifene.”Cancer.org, 17 July 2013. WEB. 17 July 2014.
  • Drukker CA , et al. Int J Cancer. 2013; 133(4): 929-36.
  • Gluck S, et al. Breast Cancer Res Treat. 2013 Jun; 139(3): 759-67.

Genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth. Using gene expression testing to help design a tailored treatment plan is called personalized medicine. These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer.

Your physician will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer. These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.

Ask your doctor to run MammaPrint ® and BluePrint ® testing together on your breast cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage. No new biopsy or surgical tissue sample is typically required. iLife Discoveries Oncology Specialists can assist your doctor in getting this done.
MammaPrint is a unique test which analyses how aggressive your breast tumor is. The result of your MammaPrint test will assist you and your physician in determining what would be the best treatment for you following your operation.
MammaPrint is most suitable if breast cancer is still at an early stage. Ask your physician whether MammaPrint would be useful in your condition.
Your physician can request the test to be performed. Please discuss this with your physician.
No, MammaPrint is not a treatment or cure. It is a tool used to make a more accurate diagnosis. It can be used to determine how aggressive your type of breast cancer is. MammaPrint will however help you decide what would be the most appropriate treatment for you.
You wish to receive the best possible breast cancer treatment. MammaPrint will enable you to choose a treatment which is specifically tailored to you. Over 75% of breast cancer patients in the Netherlands receive chemotherapy treatment, even though it is a well known fact that this heavy treatment is unnecessary for many of them. As many as half of breast cancer patients receive chemotherapy which they do not benefit from in any way, but nevertheless experience the side effects. If these women had been able to make a decision based on precise information obtained from MammaPrint, they could have
MammaPrint is suitable for all types of breast cancer at an early stage, i.e. for ER+ and ER lymph node negative and positive (1-3) tumors in stages 1 and 2.
The physician takes a small piece of tissue from the tumors which has been removed, and sends the FFPE Block of this tissue to iLife Discoveries Laboratory.
This implies that statistically there is a 30% chance of metastasis within ten years. But supplementary therapy could reduce this risk. The MammaPrint can be used to determine in greater detail what your specific risk of metastasis is. You will then know whether chemotherapy would be appropriate for your tumor.
The chances of survival are excellent. Over the past twenty years prospects have radically improved. Especially if you have been diagnosed at an early stage, your chance of being cured will be very high. The fall in death rate is greatest among women between 50 and 75 years of age, i.e. the group which is invited for national breast cancer screening.
No, a different kind of test would need to be carried out. This test focuses on the hereditary forms of breast cancer, which can be identified in the BCRA-1 or BCRA-2 gene.
It takes fifteen working days to get the MammaPrint result, and it will be sent directly to your physician.
The test is performed in a CAP, CLIA accredited & FDA approved Agendia laboratory in Netherlands.
The new MammaPrint technique was developed in the Netherlands by scientists and doctors at the Netherland’s Kanker Institute (Netherlands Cancer Institute) and Antonie van Leeuwenhoek Hospital in Amsterdam.
Researchers compared the genes of patients with early metastasis to the genes of patients with late metastasis or no metastasis at all. It emerged that 70 genes played a role in the formation of metastasis and the spread thereof.
The MammaPrint test is a huge leap forward in the field of diagnosis. Analyzing the 70 genes enables one to predict with greater precision how the cancer is going to progress in the future. This will then enable your physician to tailor your treatment with greater precision.
MammaPrint is revolutionary in that it is a highly personalized diagnostic tool. MammaPrint will reveal how your individual tumor is going to develop. MammaPrint accurately predicts the risk of metastasis. This will enable you and your physician to make a more informed choice regarding the best kind of treatment for you in your specific condition.

MammaPrint is one of the first products to facilitate tailor made medicine. Your treatment no longer follows a standard protocol, but is based on your individual profile. Your genetic makeup plays a particularly important role in cancer. Your predisposition and shortcomings which occur in your genes determine the development in your cells.

A MammaPrint is performed at Agendia’s laboratory, using microarray chip technology. A microarray is a minute (micro) rectangular plate containing tiny drops of DNA arranged in a matrix pattern (array).
Each spot on the microarray contains a piece of DNA of one particular gene, which belongs for example to a human being. In the event of a MammaPrint they would be genes from a piece of breast tissue.
Cancer is often caused by overactive genes. It becomes essential to know which specific genes are the causes of the cancer. This can be determined by using a microarray to compare the activity of the genes in healthy cells to the activity of genes in tumor cells.
MammaPrint is a 70-gene test that will assess your cancer’s risk of recurrence or how likely the cancer is to return in the future. You are given definitive results, either a Low Risk or High Risk result, with no intermediate or undetermined results. A Low Risk result means you have a 10% or 1 in 10 chance of your cancer returning. A High Risk result means you have a 29%, or 3 out of 10 chance of it returning. These results are based on a 10-year follow-up of a reference group of patients who had no additional treatment.1 A Low Risk result doesn’t guarantee that your cancer will not recur, and a High Risk result doesn’t guarantee that your cancer will. These results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions.
If you are in the Low Risk group, you have a lower chance of the cancer returning, and there is little, if any benefit to getting chemotherapy. Studies have shown the addition of Hormone therapy alone for ER-positive breast cancer can lower the risk of recurrence by up to 50%.
If you are in the High Risk group, the addition of chemotherapy can be considered as part of your treatment plan. High Risk patients can be further divided into subtypes, which can refine your treatment plan.

These subtypes provide additional information about what your tumor may respond to best: hormone therapy, chemotherapy, targeted therapy or a combination

Ask your doctor to run the Agendia Breast Cancer Test Suite on your breast cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage (FFPE tissue). No new biopsy or surgical tissue sample is usually required.

If your doctor is unfamiliar with Agendia testing, please call Customer Care at 0124-4779800, +91 8506891000 to know more about the test.

Agendia provides a summary page designed for patients to help understand their individual results and have a meaningful discussion with their doctor about treatment options.
BluePrint is a 80-gene test that uncovers your tumor’s functional molecular subtype. Molecular subtyping informs your doctor about how the tumor is functioning underneath the surface. Traditional subtyping (such as IHC or FISH) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level, to see which genes are driving the tumor’s behavior. Combined with MammaPrint, BluePrint will determine if your breast cancer is Luminal type (A or B), Basal-type or HER-2 type. These findings are important when deciding which treatment is most appropriate for your specific tumor.
MammaPrint and BluePrint provide you and your doctor deeper insight into tumor pathways, uncovering your hidden tumor biology. By combining risk of recurrence, with molecular subtyping, you get a clearer picture of how your breast cancer is functioning, leading to more informed treatment decision making. MammaPrint is the first FDA cleared breast cancer recurrence assay, and is the only breast cancer recurrence assay backed by peer-reviewed prospective outcome data.

BluePrint molecular subtyping is the most widely available molecular subtyping assay that identify your potential level of responsiveness to chemotherapy more accurately than IHC/FISH, with better correlation to long-term clinical treatment outcomes.

Click on the links below to download helpful resource materials:

New Study Could Change Breast Cancer Treatment

WKRN-TV in Nashville covers an important study of BluePrint, a molecular test for individualizing treatment of breast cancer patients, and interviews Nashville-based researcher Pat Whitworth, M.D. Also interviewed is patient Nina Vowell, who chose a treatment approach made possible by tests like BluePrint. She first received pre-operative chemotherapy to shrink her tumor, and then had breast-conserving surgery. This option helped her avoid a mastectomy. Dr. Whitworth notes that only patients who will benefit from chemotherapy should receive it. The NBRST study concluded that BluePrint may be a better guide than IHC-FISH tests in making decisions about how to treat early-stage breast cancer before surgery.

Agendia is a leading molecular diagnostic company focused on oncology that develops and markets FFPE-Based genomic diagnostic products.

A simple test with fast, individualized results

Talk with your doctor about how the MammaPrint test can help inform your treatment options. It’s simple and non-invasive.

Step 1 – Consult your doctor to send FFPE Block to the iLifediscoveries laboratory.

Step 2 – MammaPrint & BluePrint test performed on your FFPE tissue in FDA approved , CAP & CLIA accredited lab.

Step 3 – In 15 days , your report is ready for your Healthcare Provider

WE WOULD LOVE TO HEAR FROM YOU

Contact us